Australian biotech Medlab Clinical said that it has received a grant from the New South Wales government for development of a proof-of-concept intranasal vaccine based on its NanoCelle “sub-micron delivery platform” technology. The company added that it will develop the vaccine in partnership with OINDP specialist Daniela Traini of the Woolcock Institute of Medical Research as well as University of New South Wales Professor Pall Thordarson.
According to the Medlab web site, NanoCelle is a water-soluble micelle that enhances absorption and that has patent protection in Europe, the UK, Canada, Australia, and New Zealand until 2036. Medlab makes two cannabis buccal sprays based on NanoCelle technology and is developing those products as prescription therapies for oncology/pain management and mental health.
Medlab CEO Sean Hall commented, “We are extremely pleased with this outcome. Personally, I would like to thank Research Australia for making the introductions, secondly, I warmly welcome both professors, and their respective teams, who are noted academics in nucleic acid production (RNA) and nasal delivery of pharmaceutical agents. This grant and collaboration with our university partners offer a welcomed patient solution as well as a de-risked mechanism to spearhead NanoCelle into complex vaccine technologies.”
Read the Medlab Clinical press release.
